The European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment.
Medical Oncology, CHU Sart Tilman Liege & Liege University, Domaine Universitaire du Sart Tilman, B35, 4000 Liege, Belgium.
Guy
G
Jerusalem
University of Liège Hospital, GIGA Cardiovascular Sciences, Cardio-Oncology Clinic Unit, CHU Sart Tilman Liege & Liege University, Domaine Universitaire du Sart Tilman, B35, 4000 Liege, Belgium.
Marie
M
Moonen
Medical Oncology, CHU Sart Tilman Liege & Liege University, Domaine Universitaire du Sart Tilman, B35, 4000 Liege, Belgium.
Pierre
P
Freres
University of Liège Hospital, GIGA Cardiovascular Sciences, Cardio-Oncology Clinic Unit, CHU Sart Tilman Liege & Liege University, Domaine Universitaire du Sart Tilman, B35, 4000 Liege, Belgium.
Patrizio
P
Lancellotti
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000628:therapy*; D066126:Cardiotoxicity; D005060:Europe; D005260:Female; D006801:Humans; D011878:Radiotherapy / Q000009:adverse effects*; D012042:Registries; D012307:Risk Factors
D000970:Antineoplastic Agents
anthracyclines; breast cancer; cardiac toxicity; cardio-oncology; monitoring; trastuzumab